Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AB Science SA Announces Positive Results of Amyothropic Lateral Sclerosis Efficacy Experiments with Masitinib


Wednesday, 6 Nov 2013 01:00pm EST 

AB Science SA announced that the acceleration of the clinical development program in Amyothropic Lateral Sclerosis (ALS) is in line with proof of efficacy experiments with masitinib, conducted in two different models that generated positive results of increased survival. One experiment was aimed at evaluation the effect of masitinib in mice models of ALS. Administration of masitinib significantly delayed age of symptoms onset, improved grip strength and weight loss compared to control animals. Other experiment was aimed at evaluating the effect of masitinib in a transgenic rat model of ALS. Compared to control, masitinib prolonged the survival of ALS rats, delaying the progression of paralytic symptoms and weight loss, suggesting a protective effect of masitinib in motor neuron diseases. 

Related Company News

Company Quote

8.93
-0.08 -0.89%
22 Aug 2014